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Abstract Cry toxins form lytic pores in the insect midgut cells.
The role of receptor interaction in the process of protoxin
activation was analyzed. Incubation of Cry1Ab protoxin with a
single chain antibody that mimics the cadherin-like receptor and
treatment with Manduca sexta midgut juice or trypsin, resulted
in toxin preparations with high pore-forming activity in vitro.
This activity correlates with the formation of a 250 kDa
oligomer that lacks the helix K-1 of domain I. The oligomer, in
contrast with the 60 kDa monomer, was capable of membrane
insertion as judged by 8-anilino-1-naphthalenesulfonate binding.
Cry1Ab protoxin was also activated to a 250 kDa oligomer by
incubation with brush border membrane vesicles, presumably by
the action of a membrane-associated protease. Finally, a model
where receptor binding allows the efficient cleavage of K-1 and
formation of a pre-pore oligomeric structure that is efficient in
pore formation, is presented. ß 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Bacillus thuringiensis (Bt) is a bacterium that produces in-
secticidal proteins (Cry) toxic to di¡erent insect orders [1]. Cry
toxins exert their pathological e¡ect by forming lytic pores in
the membrane of insect midgut cells [2].
The Cry proteins are solubilized within the insect gut due to
the highly alkaline and reducing conditions of gut lumen. The
liberated protoxins are activated by midgut proteases to re-
lease the toxin fragment [3]. The three-dimensional structures
of some Cry toxins have been resolved [4^6] showing that they
are comprised of three domains. Domain I, a seven-K helix
bundle, is the pore-forming domain. Domain II and domain
III, composed of L-sheets, are involved in receptor binding [7].
Cry toxin binds speci¢cally to its receptors. Two Cry1A toxin
receptors have been identi¢ed as aminopeptidase-N (APN)
and cadherin-like (Bt-R1, Bt-R175) [8^14]. The debate on
whether these are functional receptors leading to pore forma-
tion is still on-going. In contrast to APN, the expression of
the cadherin-like protein from Bombyx mori, Bt-R175, on the
surface of Sf9 insect cells rendered them sensitive to Cry1Aa
toxin [11]. Also, an Heliothis virescens population resistant to
Cry1Ac toxin is mutated in a cadherin-like gene [15]. In pre-
vious work, a scFv antibody (scFv73) that inhibits binding of
Cry1A toxins to cadherin-like receptors, but not to APN, and
reduced the toxicity of Cry1Ab to Manduca sexta larvae was
characterized. Interestingly, the CDR3 region of scFv73
shared homology with an eight amino acid epitope of M.
sexta cadherin-like receptor, Bt-R1 [16]. Overall, these results
suggested that binding to cadherin-like receptor is an impor-
tant step in the Cry1A toxins mode of action.
Following binding, it is proposed that at least part of the
toxin inserts into the membrane resulting in pore formation
[1,2]. The intermolecular interaction of Cry1Ab monomers is
a necessary step for toxicity [17,18] and a tetrameric oligomer
of Cry1Ac was observed in synthetic membranes [19]. How-
ever, it has not been established if oligomer formation occurs
before (pre-pore) or after toxin insertion. Previous observa-
tions in our laboratory showed that trypsin-activated Cry1A
protoxins, resulted in toxin preparations with low pore for-
mation activity in vitro, despite the fact that they retained
toxicity [20], suggesting an incomplete activation. Also, M.
sexta midgut juice (MJ) treatment of Cry1Ab protoxin pro-
duced proteolytic cleavages inside the toxin. Two additional
nicks were identi¢ed which remove helices K-1 and K-2 of
domain I. The highest in vitro pore formation activity was
observed after helix K-1 was removed [20]. Similar results
were obtained for Cry1Ac protoxin activated with MJ from
Pieris brassica [21]. These results suggest that in vivo, further
proteolytical cleavages may occur for toxin activation.
In this work we analyzed if receptor interaction, using the
scFv73 antibody as model receptor, is a necessary step for an
e⁄cient proteolytic activation of Cry1A toxins. We show that
Cry1Ab toxin binding to the cadherin-like receptor promotes
complete proteolytic activation and a pre-pore formation that
is insertion competent leading to the formation of functional
ionic pores in vitro.
2. Materials and methods
2.1. MJ isolation and activation of Cry1Ab protoxin
M. sexta larvae were reared on arti¢cial diet. Midgut tissue was
dissected from 5th instar larvae. MJ was separated from solid material
by centrifugation and ¢ltered through 0.22 Wm ¢lters.
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Cry1Ab crystals were produced in Bt strain 407cry3 transformed
with pHT315-1Ab [16]. Cry1Ab crystal puri¢cation and protoxin sol-
ubilization were done as described [16]. For activation, 1^2 mg/ml
Cry1Ab protoxin was incubated 1 h with 1/1 ratio of scFv73. Trypsin
(1/20 ratio) or MJ (5%) was added and incubated 1 h at 37‡C. PMSF
(1 mM) was added and samples centrifuged (20 min at 12 000Ug).
For protoxin activation with brush border membrane vesicles
(BBMV), 100 nM Cry1Ab protoxin was incubated 15 min with 10
Wg BBMV, stopped with PMSF and centrifuged as above. Puri¢cation
of the activated toxins was done by size exclusion chromatography
with Superdex 200 HR 10/30 (Amersham Pharmacia Biotech, Sweden)
FPLC size exclusion as described [22]. N-terminal sequencing was
performed at the Harvard Microchemistry Facility of Harvard Uni-
versity (Cambridge, MA, USA) after 7% SDS^PAGE and transfer
onto polyvinylidene di£uoride membranes.
2.2. Western blot of Cry1Ab toxin
Activated toxin was separated in SDS^PAGE, transferred onto a
nitrocellulose membrane PVDF, blocked with slimed milk (5%) and
detected with anti-Cry1Ab polyclonal antibody (1/80 000; 1 h) and
visualized with a goat anti-rabbit antibody coupled with horseradish
peroxidase (HR) (Sigma, St. Louis, MO, USA) (1/1000; 1 h), followed
by SuperSignal chemiluminescent substrate (Pierce, Rockford, IL,
USA) as described by the manufacturers.
2.3. Puri¢cation and characterization of scFv
Escherichia coli scFv fragments were puri¢ed to homogeneity by an
Ni-agarose column, as described [16].
2.4. Preparation of BBMV
BBMV from 5th instar M. sexta larvae were prepared and dialyzed
against 150 mM KCl, 2 mM EGTA, 0.5 mM EDTA, 10 mM
HEPES^HCl pH 7.5 as reported [16]. BBMV for activation of
Cry1A protoxins were prepared as above without protease inhibitors.
2.5. Fluorescence measurements
Membrane potential was monitored with the £uorescent positively
charged dye, 3,3P-dipropylthiodicarbocyanine (Dis-C3-(5)), in an
Aminco Bowman luminescence spectrometer (Urbana, IL, USA) as
in [24].
2.6. ANS binding
Binding of 8-anilino-1-naphthalenesulfonate hemimagnesium (ANS,
15 WM, Sigma, St. Louis. MO, USA) was measured as reported [25] at
380/480 nm excitation/emission wavelengths pair.
2.7. Insect bioassay
Bioassays were performed with M. sexta neonate larvae as reported
[26]. The e¡ective doses were calculated using PROBIT analysis.
3. Results
3.1. Proteolytic activation of Cry1Ab protoxin in the presence
of scFv73 antibody
We isolated a single chain antibody (scFv73) that interfered
the interaction of Cry1Ab toxin with BBMV from M. sexta
[16]. The characterization of scFv73 led to the identi¢cation of
two discrete eight residue regions present in cadherin-like re-
ceptors from M. sexta and B. mori, that were su⁄cient to
compete binding of Cry1Ab and Cry1Aa to cadherin proteins
and to negatively a¡ect toxicity of Cry1Ab against M. sexta
larvae [16]. Therefore scFv73 can be used as a surrogate of
cadherin-like receptors.
To analyze the e¡ect of Cry toxin binding to this epitope in
the activation process, Cry1Ab protoxin was preincubated
with scFv73 at room temperature and treated afterwards
with trypsin or with MJ from M. sexta larvae. As control,
Cry1Ab protoxin was incubated with scFv45 that binds
Cry1Ab but has no e¡ect on Cry1Ab binding to Bt-R1 or
in toxicity [16]. MJ or trypsin completely degrade scFv as
judged by SDS^PAGE and Western blot (see below). In vitro
K permeability assays were performed using a £uorescent
positively charged dye (Dis-C3-(5)) sensitive to changes in
membrane potential as reported [24] in isolated M. sexta
BBMV with the di¡erent toxin preparations (Fig. 1A, Table
1). Proteolytic activation of Cry1Ab protoxin incubated with
scFv73 and treatment with MJ or trypsin resulted in toxin
preparations with high pore formation activities, in contrast
with the Cry1Ab protoxin incubated with scFv45 or treated
only with MJ or trypsin (Table 1). Also, Cry1Ab protoxin or
scFv73 alone or a mixture of both without further treatment
with proteases, showed no pore formation activity in vitro
(data not shown). Addition of 50 nM of scFv73-MJ-activated
Cry1Ab toxin to BBMV loaded with 150 mM KCl and sus-
Fig. 1. K permeability across M. sexta BBMV induced by
Cry1Ab-activated toxins. Changes in distribution of a £uorescent
dye (Dis-C3-(5)) sensitive to change in membrane potential were re-
corded as 2.5. A: Trace 1, Cry1Ab toxin activated with MJ (50
nM); trace 2, Cry1Ab toxin activated with BBMV (50 nM); trace
3, Cry1Ab toxin activated with scFv73 and MJ (50 nM). B: K
permeability of puri¢ed Cry1Ab toxins by size exclusion. Trace 1,
Cry1Ab 60 kDa monomer (30 nM) (fraction 17 of Fig. 2C); trace
2, Cry1Ab 250 kDa oligomer (6 nM) (fraction 9* of Fig. 2C); trace
3, Cry1Ab 60 kDa monomer (30 nM) (fraction 17* of Fig. 2C);
trace 4, control, bu¡er addition. The arrow on the top of the traces
corresponds to the time of toxin addition. An upward de£ection in-
dicates a membrane depolarization. Numbers in traces indicate the
¢nal K concentrations (mM).
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pended in 150 mM MeGluCl produced a fast hyperpolariza-
tion (Fig. 1A). The response of the Dis-C3-(5) dye to KCl
additions also increased, when compared to the control in
which the same amount of bu¡er was added. After each
KCl addition a new membrane potential is established, and
a depolarization is produced. Preincubation of Cry1Ab pro-
toxin with scFv73 was necessary since simultaneous addition
of scFv73 and MJ proteases resulted in no pore formation
(Table 1). Activation was further improved when scFv73
was preincubated with Cry1Ab protoxin at 37‡C, suggesting
a better interaction at this temperature (Table 1).
Bioassays were performed with toxin preparations obtained
by MJ treatment in the presence or absence of scFv73. Table
2 shows that toxin preparations obtained in the presence of
scFv73 showed similar LC50 than Cry1Ab protoxin and 10
times higher toxicity than toxin treated with MJ in absence
of scFv73.
3.2. In vitro pore formation activity correlates with
oligomer formation
Fig. 2A shows a SDS^PAGE of di¡erent samples of
Cry1Ab protoxin. A major band of 130 kDa was observed
in the Cry1Ab protoxin samples in the absence or presence of
scFv73 (Fig. 2A, lanes 1 and 2), an additional 30 kDa band
was also observed in the sample incubated with scFv73 that
corresponds to the molecular mass of the scFv molecule. In
contrast, in the Cry1Ab protoxin sample incubated with
scFv73 and treated with MJ only a 60 kDa band was observed
suggesting that scFv73 was degraded by the protease treat-
ment (Fig. 2A, lane 3). Western blot of Cry1Ab-activated
proteins, using an anti-Cry1Ab polyclonal antibody, was per-
formed. Fig. 2B shows that a major 60 kDa protein and lower
molecular mass proteins were obtained as reported [20]. How-
ever, additional higher molecular mass bands (120 and 250
kDa) that reacted with poly-Cry1Ab, were observed in toxin
preparations obtained in the presence of scFv73. The molec-
ular sizes of these proteins correspond to dimers and tet-
ramers of Cry1Ab. The samples containing the oligomers
were treated at di¡erent temperatures before loading the
gels. The same amount of the 250 kDa oligomer was observed
at 50‡C, 80‡C or boiling, implying that oligomers were highly
stable (data not shown). To analyze if scFv73 was part of the
oligomer, a Western blot using anti-mic tag antibody was
performed showing that the scFv73 was not part of the olig-
omer (data not shown). To further characterize the putative
oligomers, Cry1Ab toxin preparations obtained by MJ treat-
Fig. 2. SDS^PAGE and Western blots of activated Cry1Ab toxin. A: SDS^PAGE (10% acrylamide): lane 1, Cry1Ab protoxin; lane 2, Cry1Ab
protoxin with scFv73; and lane 3, Cry1Ab protoxin with scFv73 and treated 1 h with MJ. B: Western blotting (SDS^PAGE 7% acrylamide)
detected with an anti-Cry1Ab polyclonal antibody. Lane 1, Cry1Ab protoxin activated with scFv73 and MJ; lane 2, Cry1Ab protoxin activated
only with MJ; lane 3, Cry1Ab protoxin activated with M. sexta BBMV. C: Western blotting (SDS^PAGE 12% acrylamide) of samples from
size exclusion chromatography of Cry1Ab protoxins activated with scFv73 and MJ (*) or with MJ. Proteins were revealed with anti-Cry1Ab
polyclonal antibody. Numbers in C are the retention times of the di¡erent fractions.
Table 1
K permeability of Cry1Ab-activated toxins
Sample m3maint (K
 permeability) % K permeability
Protox. Cry1Ab+scFv73+trypsin 0.202 41
Protox. Cry1Ab+scFv73+MJ 0.392 78
Protox. Cry1Ab+scFv45+trypsin 0.049 10
Protox. Cry1Ab+scFv45+MJ 0.027 5
Protox. Cry1Ab+MJ 0.045 9
Protox. Cry1Ab+scFv73+MJ at 37‡C 0.498 100
Protox. Cry1Ab+scFv73+MJ (mixed)b 0.087 18
Protox. Cry1Ab+BBMV 0.143 29
Protox. Cry1Ab+MJ (monomer)c 0.049 (0.079)e 10 (16)
Protox. Cry1Ab+scFv73+MJ (monomer)c 0.047 (0.076) 10 (16)
Protox. Cry1Ab+scFv73+MJ (oligomer)d 0.122 (1.02) 25 (207)
Values are means of four di¡erent determinations. Standard deviations were less than 10%. 50 nM toxin for each assay except where indicated.
aThe di¡erences of the slope of the curve of each activated toxin (mtox) minus the slope of the control trace in which the same amount of bu¡-
er was added [mint] are presented.
bCry1Ab protoxin and scFv73 were not preincubated and were mixed along with the MJ.
c30 nM toxin. Proteins after size excusion chromatography of activated Cry1Ab toxin as indicated.
d60 nM toxin. Proteins after size excusion chromatography of activated Cry1Ab toxin as indicated.
eNumbers in parentheses are values obtained considering 50 nM protein concentration as the rest of the treatments.
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ment in the presence or absence of scFv73 were subject to size
exclusion chromatography and poly-Cry1Ab detection. Fig.
2C shows that a major fraction containing the monomer (60
kDa) was obtained in both toxin preparations (retention time
17 min). In this fraction, lower molecular mass proteins that
co-eluted with the 60 kDa monomer were observed. These
smaller proteins are the product of proteolysis within domain
II that co-eluted with the monomer since they remain attached
after nicking [20]. However, in the toxin preparation obtained
in the presence of scFv73 the 250 kDa oligomer (retention
time 9 min), was observed (Fig. 2C). The 120 kDa protein
was not observed after size exclusion. The same samples of the
chromatography were blotted and revealed using a monoclo-
nal 4D6 that recognizes an epitope in domain I of Cry1Ab
[23]. 4D6 only recognized the Cry1Ab monomer (data not
shown).
Finally, pore formation activity of the 250 kDa oligomer
and of 60 kDa monomers obtained after size exclusion chro-
matography was determined. Fig. 1B and Table 1 show that
only the oligomer had pore formation activity in vitro.
3.3. Oligomer formation involves cleavage after helix K-1
The amino-terminal sequences of the 60 kDa monomer and
the 250 kDa oligomer were determined. The amino terminal
sequence of the monomer (29IETGYTP) corresponds to the
beginning of helix K-1, in contrast to the oligomer
(51VPGAG) that was located between helices K-1 and K-2,
showing that the helix K-1 was removed.
3.4. ANS binding to Cry1Ab monomer and oligomer
ANS binds to solvent-accessible clusters of non-polar resi-
dues [27], which are relatively rare in the native state of solu-
ble proteins. We analyzed ANS binding to the 250 kDa olig-
omer, and to the 60 kDa monomer. Fig. 3 shows that only the
toxin preparation containing the oligomer bound ANS.
3.5. Activation of Cry1Ab toxin with membrane-associated
proteases
Cry1Ab protoxin was activated by incubation with BBMV
preparations isolated without protease inhibitors for di¡erent
times and analyzed by SDS^PAGE and Western blot with
poly-Cry1Ab. Incubation of Cry1Ab protoxin with BBMV
prepared in the absence of proteinase inhibitors for 15 min
was enough to digest the protoxin to a 60 kDa polypeptide
(Fig. 2B) suggesting the existence of proteases associated with
the BBMV. The formation of the 250 kDa oligomer (Fig. 2B),
which showed in vitro pore formation activity (Fig. 1A, Table
1) was also observed.
4. Discussion
The accepted mode of action of Cry toxins involves solubi-
lization of Cry proteins, proteolytic activation, receptor bind-
ing, membrane insertion, toxin oligomerization and ¢nally
pore formation leading to cell swelling and lysis [7]. It is
accepted that the pore is formed by the aggregation of several
monomers [17^19]. However, it is still unclear if oligomer
formation occurs before or after membrane insertion. Neither
is clear if receptor binding is important in the process of olig-
omer formation. In this work we provide evidences for an
active role of receptor binding in the process of proteolytic
activation. Moreover, our data support the formation of a
pre-pore structure that is capable of inserting into membranes.
Thus, the proposed mode of action of Cry toxins now resem-
bles the one proposed for several other pore-forming toxins in
which proteolytic cleavage after receptor binding promotes
pre-pore oligomer formation as a prerequisite for membrane
insertion [25,28^31]. We show here that cadherin binding pro-
motes e⁄cient proteolytic activation of Cry1Ab toxin that
leads to dimer and tetrameric oligomer formation. However,
the dimer was consistently observed in lower amounts than
the tetramer (Fig. 2B) and could not be detected after sepa-
ration by size exclusion suggesting that the dimer could be an
unstable intermediate in the formation of the tetramer. The
tetrameric oligomer correlates with higher in vitro pore for-
mation activity and enhanced Cry1Ab toxicity (Fig. 1B). The
similar activation with scFv73 and MJ was obtained for
Cry1Aa protoxin (data not shown).
Cry toxins do not form spontaneous oligomers in solution
in vitro [22], suggesting that in vivo the oligomer formation
may occur either after receptor binding or by lateral move-
ment of monomers in the membrane. Our data support that
the Cry1Ab oligomer is formed after receptor binding and
before membrane insertion, forming a pre-pore structure
that is insertion competent. The oligomer preferentially bound
ANS that speci¢cally reacts with solvent-accessible clusters of
non-polar residues suggesting that oligomerization is accom-
panied by exposure of a hydrophobic surface. Binding of
Cry1Ab toxin to the cadherin epitope analyzed in this work
[16] seems to be a key step in the process of protease cleavage
and pre-pore formation. However, the e⁄ciency of Cry1Ab
activation in vitro in the presence of scFv73 was low since a
large proportion of the toxin remained monomeric (Fig. 2).
A⁄nity of scFv73 to Cry1A toxins was in the range of 20^50
nM [16] in contrast with 1 nM of puri¢ed Bt-R1 [10], suggest-
ing that additional epitopes in the receptor may contribute to
the binding interaction, or other receptors might be involved
Table 2
Toxicity of Cry1Ab-activated toxins to M. sexta
Treatment LC50 (ng/cm2)a
Protoxin Cry1Ab 1 (0.5^1.7)
Protoxin Cry1Ab+scFv73+MJ 1.6 (0.78^3.01)
Protoxin Cry1Ab+MJ 20.7 (14.3^67.4)
aLC50 values and (95% con¢dence limits) calculated by probit analy-
sis.
Fig. 3. ANS binding to Cry1Ab protoxin activated in the presence
of scFv73 and MJ (1) or with MJ (2). Samples correspond to pro-
teins shown in Fig. 2B, lanes 1 and 2 respectively. After 25 s 1.5 Wg
protein of the Cry1Ab samples was added.
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(e.g. APN). Another possibility, to explain the low e⁄ciency is
that since scFv73 is degraded by the protease treatment, most
of the Cry1Ab proteins loose scFv73 binding before a proper
cleavage. The activation with BBMV was less e⁄cient than
with scFv73. It is likely that cadherin concentration in BBMV
was low compared with the excess of scFv73 used (1/1 ratio).
Also, the fact that BBMV were puri¢ed in the absence of
proteinase inhibitors could reduce even more the concentra-
tion of active receptor. This remains to be analyzed.
Our data indicate that cadherin receptor binding is involved
in proteolytic activation of Cry1Ab protoxin, promoting the
formation of an oligomeric structure which exposes hydro-
phobic residues and is active for pore formation activity.
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